NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE59156 Query DataSets for GSE59156
Status Public on Jan 01, 2016
Title MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets
Organism Homo sapiens
Experiment type Non-coding RNA profiling by array
Summary MicroRNA (miRNA) expression profiles were generated from prostate epithelial sub-populations, enriched from patient-derived benign prostatic hyperplasia (BPH, n=5), Gleason 7 treatment naïve prostate cancer (PCa, n=5) and castration-resistant prostate cancer (CRPC, n=3). Microarray expression was validated in an independent patient cohort (n=10). The analyses show that miRNA expression in epithelial sub-populations (e.g. stem cells) clustered together, irrespective of pathological status. We also discovered concordance between the miRNA expression profiles of unfractioned CRPCs, human embryonic stem cells (SCs), and prostate epithelial SCs (both, benign and malignant). miR-548c-3p was chosen as a candidate miRNA from this group to explore its utility as a CRPC biomarker and/or therapeutic target. Overexpression of miR-548c-3p was confirmed in cancer SCs (8-fold, p<0.05) and unfractionated CRPCs (1.8-fold, p<0.05). Enforced overexpression of miR-548c-3p in differentiated cells induced stem-like properties (p 0.01) and radioresistance (p<0.01). Re-analyses of published studies further revealed that miR-548c-3p is significantly overexpressed in CRPC (p<0.05) and is associated with poor recurrence-free survival (p<0.05), suggesting that miR-548c-3p is a functional biomarker for prostate cancer aggressiveness. Our results validate the prognostic and therapeutic relevance of miRNAs for advanced prostate cancer management, whilst demonstrating that resolving cell-type and differentiation-specific differences is essential to obtain clinical relevant miRNA expression profiles.
 
Overall design There are 42 samples in total: 15 benign prostatic hyperplasia, 15 prostate cancers, 9 treatment-resistant prostate cancer. There are stem cells, transit amplifying cells and committed basal cells dissected from each sample. Three PrEC samples of each three cell types can be used as reference.
 
Contributor(s) Rane JK, Scaravilli M, Ylipää A, Pellacani D, Mann VM, Simms MS, Nykter M, Collins AT, Visakorpi T, Maitland NJ
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Jul 07, 2014
Last update date Jan 19, 2017
Contact name Antti Ylipää
Organization name Tampere University of Technology
Street address Korkeakoulunkatu 1
City Tampere
ZIP/Postal code 33101
Country Finland
 
Platforms (1)
GPL14767 Agilent-021827 Human miRNA Microarray G4470C (Feature Number version)
Samples (42)
GSM1429486 normal prostate analogue - committed basal cells - sample 1
GSM1429487 normal prostate analogue - stem cells - sample 1
GSM1429488 normal prostate analogue - transit amplifying cells - sample 1
Relations
BioProject PRJNA254503

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE59156_RAW.tar 36.0 Mb (http)(custom) TAR (of TXT)
Processed data included within Sample table
| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap